Waverly Advisors LLC Has $12.45 Million Stake in Abbott Laboratories $ABT

Waverly Advisors LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 7.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,186 shares of the healthcare product maker’s stock after purchasing an additional 9,132 shares during the period. Waverly Advisors LLC’s holdings in Abbott Laboratories were worth $12,448,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ABT. California State Teachers Retirement System grew its stake in shares of Abbott Laboratories by 9,127.1% in the 2nd quarter. California State Teachers Retirement System now owns 246,828,861 shares of the healthcare product maker’s stock valued at $22,397,251,000 after buying an additional 244,153,804 shares during the period. BlackRock Inc. lifted its position in shares of Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after buying an additional 6,769,518 shares in the last quarter. State Street Corp boosted its position in Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares during the last quarter. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares during the last quarter. Finally, J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Down 0.2%

NYSE ABT opened at $105.29 on Thursday. The stock has a market cap of $182.19 billion, a P/E ratio of 34.07, a price-to-earnings-growth ratio of 1.96 and a beta of 0.59. The stock has a 50 day simple moving average of $105.30 and a two-hundred day simple moving average of $99.90. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the previous year, the firm earned $1.26 EPS. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wells Fargo & Company upped their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a research report on Thursday, August 13th. UBS Group reduced their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Finally, Bank of America decreased their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating challenging cases of atrial fibrillation. The catheter combines pulsed-field ablation (PFA) and radiofrequency (RF) energy, giving physicians greater flexibility and expanding Abbott’s cardiac rhythm-management portfolio. The device previously received a European CE mark in January 2026, and U.S. approval could support broader adoption and future revenue growth. Abbott’s dual ablation catheter lands FDA approval
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating on Abbott and maintained a $135 price target, indicating substantial potential upside from recent trading levels. The endorsement suggests the firm views Abbott’s product pipeline and long-term fundamentals favorably. TD Cowen reaffirms Abbott buy rating
• Neutral Sentiment: A comparison of Abbott and Envista focuses on which medical-products stock offers better value. Abbott’s established business and growth prospects remain attractive, but its valuation may make it less compelling to investors specifically seeking undervalued shares. NVST or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Abbott was highlighted as a potential defensive “Dividend King,” supported by a 54-year dividend-growth streak and healthcare-related catalysts. This may appeal to income-focused investors, although the article is general commentary rather than a new company announcement. If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King
• Negative Sentiment: Abbott recently underperformed the broader market in a prior session, reflecting near-term selling pressure. The decline appears market- or sentiment-driven rather than tied to a deterioration in the company’s fundamentals, but it may be tempering the immediate reaction to the FDA news. Here’s Why Abbott Fell More Than the Broader Market

Abbott Laboratories Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.